中国自主研发的抗乳腺癌新药临床研究进展

Progress of clinical research on new anti⁃breast cancer drugs independently developed in China

药物治疗是乳腺癌治疗的重要手段之一。近年来,中国乳腺癌的新药研发取得了长足进步,这些新药包括抗HER2药物、化疗药物、内分泌治疗药物和免疫治疗药物,涵盖了乳腺癌的各个分子亚型,其中许多临床研究改变了乳腺癌的临床实践。该文将对近年来中国自主研发的抗乳腺癌新药临床研究进行综述,以期为临床应用与后续研究提供参考。

Systemic therapy is one of the important means for breast cancer treatment.In recent years,China has made great progress in the research and development on new anti-breast cancer drugs,which include anti-HER2 therapy,chemotherapy,endocrine therapy and immunotherapy drugs that covers various molecular subtypes of breast cancer,and many of these clinical studies have changed the clinical practice of breast cancer treatment.Therefore,this article summarizes the clinical researches on new anti-breast cancer drugs independently developed in China in recent years,aiming to provide insights for clinical application and future research.